NCT07398287 Efficacy of L-menthol on Breathlessness in Interstitial Lung Disease
| NCT ID | NCT07398287 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Region Skane |
| Condition | Interstitial Lung Disease (ILD) |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2026-04-13 |
| Primary Completion | 2027-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 20 participants in total. It began in 2026-04-13 with a primary completion date of 2027-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to assess the effect of L-menthol on breathlessness and exercise capacity in patients with Interstitial lung disease (ILD).
Eligibility Criteria
Inclusion Criteria: * The subject has given written consent to participate in the study * Physician diagnosis of fibrosing ILD according to international guidelines * age 18 years or older * able to cycle * able to understand and talk Swedish to participate in the study procedures, as judged by the Investigators. Exclusion Criteria: * Resting peripheral oxygen saturation (SpO2) \< 92% * hospitalization or clinical instability during the last four weeks * treatment with supplementary oxygen at rest or during exercise * contraindication to exercise testing in accordance with clinical practice guidelines * expected survival shorter than six months as judged by the Investigator * medical conditions including congestive heart failure, acute coronary artery disease, neuromuscular diseases, severe psychiatric illness, and olfaction disorder.
Contact & Investigator
Zainab Ahmadi
PRINCIPAL INVESTIGATOR
Region Skåne and Lund University
Frequently Asked Questions
Who can join the NCT07398287 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Interstitial Lung Disease (ILD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07398287 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07398287 currently recruiting?
Yes, NCT07398287 is actively recruiting participants. Contact the research team at zainab.ahmadi@med.lu.se for enrollment information.
Where is the NCT07398287 trial being conducted?
This trial is being conducted at Karlskrona, Sweden, Lund, Sweden.
Who is sponsoring the NCT07398287 clinical trial?
NCT07398287 is sponsored by Region Skane. The principal investigator is Zainab Ahmadi at Region Skåne and Lund University. The trial plans to enroll 20 participants.